Breast Atypical Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma in Situ
Conditions
Brief summary
The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).
Detailed description
Women with atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) are at increased risk of breast cancer (BC) (\ 1-2 % per year). Over two decades ago, placebo-controlled randomized trials established that oral tamoxifen (20 mg/day) reduces breast cancer risk by 50% in generally defined high risk women, with \ 70% reduction in women at high risk specifically due to atypical hyperplasia.\[1\] Years later, the side effects and toxicity of oral tamoxifen at 20 mg/day remain a significant barrier to its uptake and longterm compliance.\[2, 3\] To address the issue of toxicity, two main strategies have been pursued: 1) using a lower dose of oral tamoxifen, and 2) using a topical formulation of tamoxifen to avoid systemic side effects. The investigators will perform a prospective study of women with AH or LCIS who will take a short course of prevention therapy; breast tissue samples will be evaluated pre- and post-therapy to identify and evaluate very early biomarkers of response. The overall goal of the study is to evaluate short-term changes in background breast tissue induced by either low-dose oral tamoxifen or topical 4-OHT gel in women with AH or LCIS.
Interventions
DRUGTamoxifen
Oral Tamoxifen 10 mg/day
DRUGTopical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day
Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day
DRUGPlacebo
placebo pill or placebo gel
OTHERQuestionnaire Administration
Ancillary studies
Sponsors
Mayo Clinic
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Subjects with be randomized by MedidataRave and Pharmacy.
Intervention model description
Subjects will be randomized 2:2:1 with either Oral Tamoxifen 10 mg/day * gel placebo, Topical 4-OHT gel 4 mg/each breast/day * oral placebo, or Control Oral and gel placebo for 4 weeks of treatment.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Willing to return to enrolling institution for follow-up * Willing to complete required testing * Ability to complete questionnaire by themselves or with assistance * Female (sex that was assigned at birth) * Ipsilateral intact breast with histology confirmation of atypical ductal or lobular hyperplasia, or lobular carcinoma in situ (LCIS), within the last 12 months, whether surgically excised or not.; OR neither AH nor LCIS but increased breast cancer risk defined as either: * Gail model (Breast Cancer Risk Assessment Tool) 5 year breast cancer risk of \>= 3%, or * International Breast Intervention Study model 10 year breast cancer risk of \>= 5%. * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 (Karnofsky \>= 70%) * The effects of topical afimoxifene (4-OHT) gel on the developing human fetus at the recommended therapeutic dose are unknown. However, oral tamoxifen is Pregnancy Category D-positive evidence of human fetal risk. For this reason, and because triphenylethylene antiestrogens, including tamoxifen, are known to be teratogenic, women of childbearing potential and their male partners must agree to use at least one effective form of birth control (abstinence is not an allowed method) prior to study entry and for the duration of study participation, and for 2 months following the last dose of study medications (participant can resume oral birth control pills for effective birth control measures after post-treatment biopsy is done). Effective birth control methods during treatment are: copper and Mirena intrauterine device (IUD), diaphragm/cervical cap/shield, spermicide, contraceptive sponge, condoms. Tubal Ligation is an acceptable method of birth control. Women of childbearing potential must have a negative pregnancy test within five days before starting study medications. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. * Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e. tanning beds) for the duration of the study. * Participants must have acceptable organ and marrow function as judged by treating physician's evaluation of baseline laboratory data. * Negative pregnancy (serum or urine) test if of childbearing potential and/or follicle stimulating hormone (FSH) to verify menopausal status.
Exclusion criteria
* Clinically suspicious mass/lesions * Breast cancer in the past 5 years. * Patients with any history of venous thromboembolic disease, regardless of timeframe (history of varicose veins and superficial phlebitis is allowed). * Current pregnancy or lactation. * History of other prior breast cancer-specific therapy within the previous 2 years (chemotherapy, anti-HER2 agents, endocrine agents, everolimus, CDK4-6 inhibitors). * Cytotoxic chemotherapy for any indication in last 2 years. * Prior use of selective estrogen receptor modulator (SERMS) or AIs including tamoxifen, raloxifene, anastrozole, letrozole, or exemestane for prevention or therapy within the past 5 years unless: * Use was less than 6 months duration in the past 5 years and not used in the 1 year prior to enrollment, or * Use was no greater than 2 months duration in the past 1 year and not used in the 6 months prior to enrollment. * Exogenous sex steroid, including oral contraceptive pill use within 1 month prior to pretreatment breast biopsy. Use of vaginally administered estrogens and hormone coated IUD such as Mirena is permitted. * History of any prior ipsilateral breast radiotherapy. Previous unilateral radiation of the contralateral side is allowed. * Skin lesions on the breast that disrupt the stratum corneum (e.g., eczema, ulceration). * History of endometrial neoplasia * Current smoker. Cessation for at least 6 weeks * Current users of potent inhibitors of tamoxifen metabolism. The potent inhibitors of tamoxifen metabolism are: bupropion, cinacalcet, fluoxetine, paroxetine, quinidine. * Participants may not be receiving any other investigational agents within 90 days of enrollment or during this study. * History of allergic reactions to tamoxifen. * Uncontrolled intercurrent illness that in the judgement of the treating physician would make them unsuitable for study participation * Current use of anticoagulation medications. * Patients who are breastfeeding. * Hemoglobin \< 10 g/dL (within 30 days of randomization). * Leukocytes \< 3,000/microliter (within 30 days of randomization). * Platelets \< 100,000/microliter (within 30 days of randomization). * Total bilirubin \> 1.5 x institutional upper limit of normal (ULN) (within 30 days of randomization). * Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT) \> 1.5 x ULN (within 30 days of randomization). * Alanine aminotransferase (ALT) serum glutamate pyruvate transaminase (SGPT) \> 1.5 x ULN (within 30 days of randomization). * Alkaline phosphatase, S \> 1.5 x ULN (within 30 days of randomization). * Albumin, S \> 1.5 x ULN (within 30 days of randomization). * Protein, total, S \> 1.5 x ULN (within 30 days of randomization). * Creatinine \> 1.5 x ULN (within 30 days of randomization). * Antithrombin III \<80% of normal. * Fibrinogen \>1000 mg/dL. * Patients who are taking any medications, herbal products, or over the counter (OTC) products that are moderate or strong CYP2D6 inhibitors or CYP3A inducers. Patients should also refrain from starting any drug or product with these properties during the study. This is to avoid any potential interactions with tamoxifen or 4-OHT. * Clinically significant arrhythmia requiring ongoing medication for control / treatment, especially those with high risk of QT prolonging effects. * Identification of a clinically suspicious mass on examination.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Median Lobular Ki67 From Pre-Tamoxifen Breast Biopsy to On-Tamoxifen Biopsy With 4 Weeks of Intervention | Pre-biopsy to post-biopsy following 4 weeks of intervention | All patients received an oral pill and a topical gel. Prior to assessing non-inferiority of 4-OHT Gel compared to Oral Tamoxifen, treatment effect was assessed within each group by testing for a significant reduction in median lobular Ki67 between PreTam and OnTam biopsy. Median lobular Ki67 is assessed using the percentage of cells stained across all lobules separately at PreTam and OnTam timepoints, evaluated for a difference in median calculated change. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAmy Degnim, M.D.
Mayo Clinic
Participant flow
Pre-assignment details
Sixty-five participants were initially enrolled. One participant was a screen failure, and three withdrew from study prior to beginning the intervention.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Customized 18 - 21 years | 0 Participants |
| Age, Customized <18 years | 0 Participants |
| Age, Customized 22 - 29 years | 0 Participants |
| Age, Customized 30 - 39 years | 2 Participants |
| Age, Customized 40 - 49 years | 18 Participants |
| Age, Customized 50 - 59 years | 24 Participants |
| Age, Customized 60 - 69 years | 11 Participants |
| Age, Customized 70 - 79 years | 6 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 21 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 52 Participants |
| Region of Enrollment United States | 12 participants |
| Sex: Female, Male Female | 61 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 25 | 0 / 24 | 0 / 12 |
| other Total, other adverse events | 22 / 25 | 21 / 24 | 8 / 12 |
| serious Total, serious adverse events | 0 / 25 | 0 / 24 | 0 / 12 |
Outcome results
None listed